Powered Presicion Drug Design HANGZHOU, China and LONDON, March 07, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical stage ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD ...

The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with ...

Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...

The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...

“There’s pretty good preclinical evidence that there is synergistic activity when radiation therapy, and possibly also alkylating chemotherapy, is combined with a WEE1 inhibitor,” says Roth.

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor ...